Mylan Recalls Ciprofloxacin Tablets Due to Manufacturing Deviations
Mylan Pharmaceuticals is recalling 521 bottles of Ciprofloxacin 250 mg tablets because they were not manufactured according to Good Manufacturing Practices.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly identifies the agency classification as Class II. According to the severity rubric, FDA Class II recalls are assigned a score of 4 (Severe), as the agency's own classification mandates a minimum score of 4.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling 521 bottles of Ciprofloxacin Tablets, USP, 250 mg, 100-count bottles (NDC 0378-7097-01). The affected lots are 3032075 and 3032076. The products were distributed nationwide and in Puerto Rico.
The recall was initiated because the pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices (CGMP Deviations). This classification is designated as Class II by the FDA.
Consumers who have these specific lot numbers should stop using the medication and contact their healthcare provider or pharmacist for guidance on obtaining a replacement.
The recalled product
- Product
- Ciprofloxacin Tablets, USP, 250 mg, 100-count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., NDC 0378-7097-01
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Antibiotic
- Affected units
- 521
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 3032075
- 3032076
Distribution
Part of a larger recall action
This product is one of 12 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 12 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Prasugrel Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- SevereMylan Recalls Ciprofloxacin Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2015-01-28
- HighMylan Recalls Loxapine Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2018-05-30
- SevereMylan Amlodipine Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2016-08-31
- ModerateMylan Lamotrigine Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2015-01-28
- ModerateMylan Recalls Prednisolone Sodium Phosphate Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2018-05-30
- ModerateMylan Recalls Capecitabine Tablets Due to Dissolution Failures
FDA (Drugs) · 2015-07-15